多西他赛、奈达铂联合放疗对食管癌术后患者生存期及肿瘤标志物影响

Effect of Docetaxel and Nedaplatin Combined with Radiotherapy on Survival and Tumor Markers of Patients with Esophageal Cancer

目的:探究多西他赛加奈达铂联合放疗对食管癌术后患者生存期及肿瘤标志物影响。方法:选取郑州大学第一附属医院2019年1月—2020年3月收治的食管癌患者95例,按照随机数表分组,分为对照组47例,研究组48例,两组患者均行根治性手术治疗,对照组采用卡培他滨加奥沙利铂(XELOX)化疗方案治疗,研究组在XELOX的基础上联合多西他赛加奈达铂化疗方案治疗,观察两组患者临床疗效、治疗前3 d及治疗后1个月患者血清血清癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、鳞状上皮细胞癌相关抗原(SCC)水平及治疗过程中患者毒副反应发生情况。结果:研究组的疾病控制率明显高于对照组,差异有统计学意义(χ^(2)=6.344,P<0.05)。治疗前3 d,两组患者血清CEA、CA19-9、SCC水平对比差异无统计学意义(t=0.282、0.171、0.263,P>0.05),治疗后1个月,两组患者血清CEA、CA19-9、SCC水平均比治疗前低,且研究组血清CEA、CA19-9、SCC水平低于对照组,差异有统计学意义(t=20.126、12.371、15.231,P<0.05)。治疗过程中研究组的毒副反应总发生率略低于对照组,差异有统计学意义(χ^(2)=0.147,P<0.05)。结论:多西他赛加奈达铂联合治疗XELOX化疗方案治疗食管癌患者可明显提高临床疗效,提高疾病控制率,降低患者血清肿瘤标志物水平,且药物的安全性良好,临床上值得推广应用。

Objective:To explore the effect of docetaxel plus nedaplatin combined with radiotherapy on the survival and tumor markers of patients with esophageal cancer after surgery.Methods:A total of 95 patients with esophageal cancer admitted to the hospital from January 2019 to March 2020 were selected and grouped according to a random number table.They were divided into control group(47 cases)and study group(48 cases).Both groups received radical treatment,and the control group was treated with capecitabine plus oxaliplatin(XELOX)chemotherapy,and the study group was treated with docetaxel plus nedaplatin chemotherapy on the basis of XELOX.The clinical efficacy and treatment Serum carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9),squamous cell carcinoma-associated antigen(SCC)levels in the patient’s serum during the first 3 d and 1 month after treatment and the occurrence of side effects during treatment of the two groups were observed.Results:The disease control rate of the study group was significantly higher than that of the control group,with statistically significant difference(χ^(2)=6.344,P<0.05).3 d before treatment,there was no statistically significant difference in serum CEA,CA19-9 and SCC levels between the two groups(t=0.282,0.171,0.263,P>0.05).1 month after treatment,the serum levels of CEA,CA19-9 and SCC in the two groups were lower than before treatment.The serum levels of CEA,CA19-9 and SCC in the study group were lower than those in the control group,with statistically significant difference(t=20.126,12.371,15.231,P<0.05).The total incidence of side effects in the study group was slightly lower than that in the control group,with statistically significant difference(χ^(2)=0.147,P<0.05).Conclusion:The combination of docetaxel and nedaplatin in the treatment of esophageal cancer patients with XELOX chemotherapy can significantly improve the clinical efficacy,improve disease control rate,and reduce the level of serum tumor markers in patients.The drug has good safety and is worthy of clinical application.